Evaluation of resistance to low pH and bile salts of human Lactobacillus spp. isolates

There are nearly 100 trillion bacteria in the intestine that together form the intestinal microbiota. They are 'good' bacteria because they help to maintain a physiological balance and are called probiotics. Probiotics must have some important characteristics: be safe for humans, be resistant to the low pH in the stomach, as well as bile salts and pancreatic juice. Indeed, their survival is the most important factor, so that they can arrive alive in the intestine and are able to form colonies, at least temporarily. The aim of our study was the evaluation of resistance of Lactobacillus isolates from fecal and oral swabs compared to that found in a commercial product. Seven strains were randomly chosen: L. jensenii, L. gasseri, L. salivarius, L. fermentum, L. rhamnosus, L. crispatus, and L. delbrueckii. We observed a large variability in the results: L. gasseri and L. fermentum were the most resistance to low pH, while only L. gasseri showed the best survival rate to bile salts. Interestingly, the commercial product did not show tolerance to both low pH and bile salts

ENDOSYMBIONTS OF ENTOMOPATHOGENIC NEMATODES FROM SOUTH ITALY:A PHENOTYPIC STUDY

We examined different Xenorhabdusstrains (five of X. bovieniiand two of X. kozodoii), obtained from EPNisolates belonging to the genus Steinernema(S. feltiae, S. ichnusae, S. apuliae, S. vulcanicum) of different geographicorigin by both genotypic and phenotypic analysis. Common laboratory assays were done for traits such as antibioticresistance, haemolytic activity, lactose utilisation, biofilm production, chosen as the least selectable traits for EPN life-cycle, and thus as (presumably) neutral traits. As selective marker, the activity of the endosymbiont’s toxins was verified inan in vivoassay on G. mellonellalarvae. Genotyping done by 16S partial sequencing was used for identification purposes.Xenorhabdusbovieniiisolates showed a broad phenotypic spectrum; on the other hand, X. kozodoiishowed a less degreeof phenotypic variation, reduced ability of biofilm production and conspicuous β-galactosidase activity. However, all thestrains were able to kill G. mellonellalarvae with high efficiency

Nuclear Magnetic Resonance Structure and Mutational Analysis of the Lactococcin A Immunity Protein

The class IId bacteriocin lactococcin A and the pediocin-like bacteriocins induce membrane leakage and cell death by specifically binding the mannose phophotransferase system (man-PTS) on their target cells. The bacteriocins’ cognate immunity proteins that protect the producer cell from its own bacteriocin recognize and bind to the bacteriocin–man-PTS complex and thereby block membrane leakage. In this study, we have determined the three-dimensional structure of the lactococcin A immunity protein (LciA) by the use of nuclear magnetic resonance spectroscopy. LciA forms a four-helix bundle structure with a flexible C-terminal tail. Despite the low degree of sequence similarity between LciA and the pediocin-like immunity proteins, they share the same fold. However, there are certain differences between the structures. The C-terminal helix in LciA is considerably shorter than that observed in the pediocin-like immunity proteins, and the surface potentials of the immunity proteins differ. Truncated variants of LciA in which 6 or 10 of the C-terminal residues were removed yielded a reduced degree of protection, indicating that the unstructured C-terminal tail is important for the functionality of the immunity proteins

Lactobacillus rhamnosus AD3 as a Promising Alternative for Probiotic Products

Lactobacillus strains dominate the vaginal habitat and they are associated with a lower risk of genital infections. In addition, they contribute to the conservation of the vaginal microbiota by producing postbiotic agents. Previous studies have shown that their predominance involves antimicrobial activity against urogenital pathologies. In this context, probiotics may improve treatment outcomes. The aim of this study was to evaluate the probiotic properties of lactobacilli strains of vaginal origin using a multidisciplinary approach. For this purpose, safety criteria, ability to resist at low pH and bile salts, antimicrobial activity, ability to produce biofilm, capacity to produce hydrogen peroxide and more importantly, auto-aggregation, co-aggregation (with Candida spp.) and adhesion to human cells were evaluated. The strains belonged to the species of L. crispatus, L. gasseri, L. rhamnosus and L. delbruckii. Among these, a strain of L. rhamnosus named AD3 showed the best probiotic properties. As probiotics are already in use in many clinical practice and there are no major safety concerns, L. rhamnosus AD3 showed promise in becoming a prevention and complementary treatment option for urogenital diseases. Indeed, these results suggest that strain L. rhamnosus AD3 is non-pathogenic and likely to be safe for human consumption. This study revealed the great amensalistic properties of a new L. rhamnosus strain which can aim to be used as probiotic in pharmaceutical applications

New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created a severe global health crisis. In this paper, we used docking and simulation methods to identify potential targets and the mechanism of action of chloroquine (CQ) and hydroxychloroquine (HCQ) against SARS-CoV-2. Our results showed that both CQ and HCQ influenced the functionality of the envelope (E) protein, necessary in the maturation processes of the virus, due to interactions that modify the flexibility of the protein structure. Furthermore, CQ and HCQ also influenced the proofreading and capping of viral RNA in SARS-CoV-2, performed by nsp10/nsp14 and nsp10/nsp16. In particular, HCQ demonstrated a better energy binding with the examined targets compared to CQ, probably due to the hydrogen bonding of the hydroxyl group of HCQ with polar amino acid residues

Colistin and kanamycin together in association with Coridothymus capitatus to enhance their antimicrobial activity and fight multidrug resistance pathogens

It should be remembered that bacteria continue to spread and develop new types of resistance, so further actions are needed to deal with antibiotic resistance. As a result, antibacterial drugs have become less effective, resulting in the accelerated discovery of available alternative treatments, including essential oils. The aim of this work was to intensify and promote the action of two antibiotics, kanamycin, and colistin, to fight antibiotic resistance thanks to the action of essential oil obtained from the flowers of Coridothymus capitatus grown on the Iblei mountains. To this end, a comparison of biological and chemical assays was carried out. The results showed a broad antimicrobial power of the essential oil itself and a great synergistic activity in combination with Kanamycin and Colistin against multidrug-resistant bacteria. These combinations increased the range of antibiotics, leading us to speculate that it could be incorporated into new pharmaceutical formulations for therapies of infections caused by increasingly dangerous bacteria. Antibiotic resistance represents an ever-greater danger to human health. This work re-evaluates the use of colistin and kanamycin thanks to the synergistic action found with the addition of a natural substance to pave the way for new therapeutic strategies

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience

Asthma is a chronic inflammatory condition involving the airways with varying pathophysiological mechanisms, clinical symptoms and outcomes, generally controlled by conventional therapies including inhaled corticosteroids and long-acting β 2 agonists. However, these therapies are unable to successfully control symptoms in about 5–10% of severe asthma patients. Atopic asthma, characterized by high immunoglobulin (Ig)E or eosinophilia, represents about 50% of asthmatic patients. Interleukin (IL)-5 is the main cytokine responsible of activation of eosinophils, hence therapeutic strategies have been investigated and developed for clinical use. Biologics targeting IL-5 and its receptor (first mepolizumab and subsequently, reslizumab and benralizumab), have been recently approved and used as add-on therapy for severe eosinophilic asthma resulting in a reduction in the circulating eosinophil count, improvement in lung function and exacerbation reduction in asthma patients. Despite these biologics having been approved for stratified severe asthma patients that remain uncontrolled with high doses of conventional therapy, a number of patients may be eligible for more than one biologic. Presently, the lack of head-to-head studies comparing the biological agents among themselves and with conventional therapy make the choice of optimal therapy for each patient a challenge for clinicians. Moreover, discontinuation of these treatments, implications for efficacy or adverse events, in particular in long-term treatment, and needs for useful biomarkers are still matters of debate. In this review we evaluate to date, the evidence on mepolizumab that seems to demonstrate it is a well-tolerated and efficacious regimen for use in severe eosinophilic asthma, though more studies are still required